Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
A-005 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose (SAD) | EXPERIMENTAL | - |
| Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | - |
| Part C: Lumbar Puncture | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| A-005 | DRUG | Single oral dose of A-005 |
| Placebo | DRUG | A-005 matched placebo |
Inclusion Criteria: * Healthy, adult, male or female 19-55 years of age, inclusive, at the screening visit. * Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit. * Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles,...
A-005 is an investigational small molecule drug being developed by Alumis Inc. It is a tyrosine kinase 2 (TYK2) inhibitor that has been studied in a Phase 1 clinical trial in healthy volunteers. The specific diseases or conditions it may treat have not been disclosed.
A-005 targets tyrosine kinase 2, also known as TYK2. TYK2 is a member of the Janus kinase family of kinases. By targeting TYK2, A-005 is designed to modulate signaling pathways associated with this kinase. Alumis Inc. is developing A-005 as a small molecule therapeutic.
A-005 is being developed by Alumis Inc., which trades on the Nasdaq under the ticker symbol ALMS. Alumis is a clinical-stage biopharmaceutical company. The company is responsible for the research and development of A-005 as an investigational therapy.
A-005 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. A-005 is investigational and has not been approved by the FDA for any indication. Further clinical development would be required before any potential approval.
A-005 has been evaluated in one completed Phase 1 clinical trial, NCT07442149. The study was titled "An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005." It enrolled 135 healthy volunteers in the United States and was randomized, double-blind, and controlled.